Immutep Limited
IMMP
Rank in Stocks
#25685
Immutep Limited, a biotechnology company, engages in developing novel... Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The companyโs product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Share Price
$3.80
Last synced: 2026-11-09
Market Cap
$24.48M
Change (1 day)
13.77%
Change (1 year)
113.48%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Immutep Limited (IMMP)
Category
Healthcare
EPS for Immutep Limited (IMMP)
EPS as of June 2026 TTM: $-7.55
According to Immutep Limited's latest financial reports, its current EPS (TTM) is $-7.55. At the end of 2025 the company had an EPS of $-5.56, a decrease compared to its 2024 EPS of $-4.75.
EPS history for Immutep Limited from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-7.55 | 35.79% |
| 2025 | $-5.56 | 16.87% |
| 2024 | $-4.75 | -19.47% |
| 2023 | $-5.90 | 14.42% |
| 2022 | $-5.16 | -30.50% |
| 2021 | $-7.42 | 62.51% |
| 2020 | $-4.57 | -30.66% |
| 2019 | $-6.59 | -6.96% |
| 2018 | $-7.08 | 4.01% |
| 2017 | $-6.81 | -83.08% |
| 2016 | $-40.23 | 30.62% |
| 2015 | $-30.80 | 48.41% |
| 2014 | $-20.75 | -18.90% |
| 2013 | $-25.59 | -34.12% |
| 2012 | $-38.84 | -51.05% |
| 2011 | $-79.35 | 134.23% |
| 2010 | $-33.88 | 179.86% |
| 2009 | $-12.10 | 3.26% |
| 2008 | $-11.72 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -307.41% |
US
|
|
| $-7.07 | -6.36% |
US
|
|
| $-5.29 | -29.93% |
AU
|
|
| $12.88 | -270.60% |
BE
|
|
| $21.56 | -385.56% |
NL
|
Questions about Immutep Limited's earnings per share (EPS)
What is Immutep Limited's earnings per share (EPS)?
Immutep Limited's earnings per share (EPS) over the last twelve months is $-7.55, as of Jun 2026.
What was Immutep Limited's earnings per share (EPS) in 2025?
In 2025, Immutep Limited's earnings per share (EPS) was $-5.56, compared with $-4.75 in 2024.
How has Immutep Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Immutep Limited's earnings per share (EPS) was highest in 2020 ($-4.57) and lowest in 2021 ($-7.42).
How does Immutep Limited's earnings per share (EPS) compare with similar companies?
Immutep Limited's earnings per share (EPS) ($-7.55) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.